Shares of Flexion Therapeutics Inc. (NASDAQ:FLXN) were up 6.5% during trading on Thursday . The stock traded as high as $17.24 and last traded at $16.94, with a volume of 288,905 shares changing hands. The stock had previously closed at $15.90.

Several analysts have commented on FLXN shares. Cantor Fitzgerald reissued a “buy” rating and issued a $44.00 price objective on shares of Flexion Therapeutics in a report on Tuesday, April 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Flexion Therapeutics in a research note on Monday, April 4th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, June 30th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, June 30th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $33.17.

The company’s market cap is $363.45 million. The firm has a 50-day moving average price of $15.05 and a 200-day moving average price of $12.69.

Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings data on Thursday, May 12th. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.17. On average, equities research analysts forecast that Flexion Therapeutics Inc. will post ($2.84) EPS for the current fiscal year.

In other Flexion Therapeutics news, Director Samuel D. Colella bought 714,285 shares of the business’s stock in a transaction dated Wednesday, June 8th. The stock was acquired at an average cost of $14.00 per share, with a total value of $9,999,990.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Samuel D. Colella bought 25,504 shares of the business’s stock in a transaction dated Tuesday, June 21st. The shares were acquired at an average cost of $13.71 per share, with a total value of $349,659.84. Following the completion of the purchase, the director now owns 3,435 shares in the company, valued at approximately $47,093.85. The disclosure for this purchase can be found here.

Several institutional investors have modified their holdings of FLXN. Jennison Associates increased its position in shares of Flexion Therapeutics by 35.1% in the third quarter. Jennison Associates now owns 2,831,268 shares of the specialty pharmaceutical company’s stock worth $42,073,000 after buying an additional 736,261 shares during the period. Schroder Investment Management Group increased its position in shares of Flexion Therapeutics by 21.0% in the fourth quarter. Schroder Investment Management Group now owns 470,200 shares of the specialty pharmaceutical company’s stock worth $9,061,000 after buying an additional 81,500 shares during the period. Jennison Associates LLC increased its position in shares of Flexion Therapeutics by 2.7% in the fourth quarter. Jennison Associates LLC now owns 2,907,755 shares of the specialty pharmaceutical company’s stock worth $56,032,000 after buying an additional 76,487 shares during the period. Finally, Wells Fargo & Company MN increased its position in shares of Flexion Therapeutics by 16.2% in the fourth quarter. Wells Fargo & Company MN now owns 430,545 shares of the specialty pharmaceutical company’s stock worth $8,296,000 after buying an additional 59,866 shares during the period.

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.